INFLUENCE OF SACUBITRIL/VALSARTAN ON GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES AND HEART FAILURE WITH REDUCED EJECTION FRACTION

Jelena P. Seferovic,Sara B. Seidelmann,Brian Clagett,Milton Packer,Michael Zile,Jean-L. Rouleau,Karl Swedberg,Martin Lefkowitz,Victor Shi,Akshay S. Desai,John J.V. McMurray,Scott D. Solomon

INFLUENCE OF SACUBITRIL/VALSARTAN ON GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES AND HEART FAILURE WITH REDUCED EJECTION FRACTION

2017

Jelena P. Seferovic
Sara B. Seidelmann
Brian Clagett
Milton Packer
Michael Zile
Jean-L. Rouleau
Karl Swedberg
Martin Lefkowitz
Victor Shi
Akshay S. Desai
John J.V. McMurray
Scott D. Solomon

Background: Type 2 diabetes (T2DM) is an independent risk factor for heart failure progression. Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor, improves morbidity and mortality in patients with heart failure with reduced ejection fraction (HFrEF) and was shown to improve

Keywords:

Sacubitril, Valsartan
Heart failure
Type 2 diabetes
Valsartan
Glycemic
Sacubitril
Internal medicine
Cardiology
Renin–angiotensin system
Ejection fraction
Medicine
Diabetes mellitus

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations